Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 17.0% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health (NYSE: HIMS) provides telehealth services and personalized health products.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 17.0% on Dec 19, 2024 18:10

• The stock of Hims & Hers Health saw significant downward movement today.
• This decline could be linked to the U.S. Food and Drug Administration's statement about tirzepatide injection shortages affecting the company's pharmaceutical line.
• Despite the recent decrease, the company has demonstrated promising growth potential with substantial revenues and subscriber numbers, suggesting a favorable outlook ahead if they can tackle supply chain issues effectively.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Hims & Hers Health Are Falling Today: What's Going On? - Hims & Hers Health ( NYSE:HIMS )

Hims & Hers Health, Inc. HIMS are trading lower Thursday. The U.S. Food and Drug Administration issued a new decision about tirzepatide injection shortages. Here's what you need to know. What To Know: The FDA announced today that the shortage of tirzepatide injections, a GLP-1 medication, has ...

https://www.benzinga.com/trading-ideas/movers/24/12/42599094/hims-hers-health-are-falling-today-whats-going-on

Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment - Hims & Hers Health ( NYSE:HIMS )

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims & Hers Health. Looking at options history for Hims & Hers Health HIMS we detected 18 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish ...

https://www.benzinga.com/insights/options/24/12/42537551/hims-hers-health-options-trading-a-deep-dive-into-market-sentiment

HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?

Hims & Hers Health sees robust 2024 growth with $401.6-million Q3 revenues (+77% YoY), 2M+ subscribers and plans to exceed $1.5B in revenues in 2024. Where will the stock go?

https://www.zacks.com/stock/news/2383735/hims-stock-surges-43-in-a-month-will-the-uptrend-continue-further

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Ethena ($ENA) Crypto Forecast: Up 5.9% Today

Aptos ($APT) Crypto Forecast: Down 5.5% Today

Cardano ($ADA) Crypto Forecast: Down 5.0% Today

Immutable ($IMX) Crypto Forecast: Down 5.1% Today

Maker ($MKR) Crypto Forecast: Down 5.3% Today

Sui ($SUI) Crypto Forecast: Down 5.2% Today

Memecoin ($MEME) Crypto Forecast: Down 5.1% Today

Polkadot ($DOT) Crypto Forecast: Down 5.0% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.0% Today

Hims & Hers Health Inc. Price History

18.10.2024 - HIMS Stock was up 5.4%

• The bullish movement in HIMS stock could be attributed to the company's efforts to enhance its offerings and expand its health and wellness products and services.
• The positive sentiment towards HIMS could also be influenced by the bullish stance taken by investors with significant capital.
• The stock might have also benefited from the overall market optimism or specific sector trends, despite potential macro challenges that could impact its performance.
• The dip in HIMS stock price due to Amazon's new pricing strategy for telehealth services might have been overshadowed by the positive developments and investor sentiment, leading to the overall bullish movement.

18.10.2024 - HIMS Stock was up 7.2%

• The bullish movement in HIMS stock could be linked to the interest of deep-pocketed investors in the company, as shown by significant options trading trends favoring Hims & Hers Health.
• Though there was a recent decrease in stock price over the past month, the notable increase in the stock price over the past year may have boosted investor confidence, leading to today's spike.
• The negative reaction to a competitor's new upfront pricing for telehealth services may have initially caused a dip in HIMS stock. However, the subsequent recovery and bullish movement suggest that investors are more focused on the company's growth potential and product expansions.
• HIMS' initiatives to improve its offerings and expand its health and wellness product range might have positively impacted investor sentiment, overshadowing potential macro challenges that could affect its future performance.

02.11.2024 - HIMS Stock was down 5.0%

• Despite increased options activity pointing towards optimism among investors, Hims & Hers Health (HIMS) faced significant downward movement today.
• Speculation around Marty Makary's potential nomination by President-elect Donald Trump as FDA head initially influenced stock performance, but various market conditions or internal factors likely drove the bearish trajectory.
• Unspecified internal factors within the company may have contributed to investor negativity, overshadowing positive news regarding FDA leadership appointments.
• Traders should monitor forthcoming updates from Hims & Hers Health to gain insight into the reasons behind the current bearish market movement.

26.10.2024 - HIMS Stock was up 6.2%

• Hims & Hers Health stock saw a significant increase following the nomination of Marty Makary by President-elect Donald Trump to lead the FDA, suggesting possible positive regulatory changes in healthcare.
• The market reacted favorably to this news, as a new FDA leader could bring reforms that benefit companies like Hims & Hers Health in the healthcare industry.
• Investors view this development as a notable opportunity for Hims & Hers Health to enhance its telehealth services and product offerings in a potentially favorable regulatory environment.

18.11.2024 - HIMS Stock was down 5.1%

• Despite recent positive news about robust revenue growth and subscriber numbers, HIMS stock experienced a bearish trend today.
• The bullish stance taken by whales and investors in the options market did not translate into a positive movement in the stock price.
• It is possible that profit-taking or market sentiment shifts led to the bearish movement, despite the optimistic outlook for the company's future growth.
• Investors may be cautious about the sustainability of Hims & Hers Health's growth trajectory, leading to the sell-off seen in the stock today.

13.10.2024 - HIMS Stock was up 5.3%

• HIMS stock has shown significant gains since the Q3 earnings report, signaling favorable investor sentiment and confidence in the company's growth prospects.
• The rise in earnings estimates indicates investor optimism about the company's future performance, driving a bullish trend in the stock.
• Deep-pocketed investors' bullish stance on HIMS options has further bolstered the stock's positive momentum, showcasing strong support for the company's potential.
• The bullish movement in HIMS stock is attributed to the company's strategic initiatives to enhance its offerings and expand its product range, despite potential macro challenges that could impact its performance.

12.11.2024 - HIMS Stock was up 9.8%

• Unusual options activity on HIMS suggests a bullish stance by investors with significant capital.
• The increased interest in call options could indicate a positive sentiment and potential upside in the stock.
• This bullish movement could be driven by expectations of strong financial performance or potential positive developments within the company, leading to increased investor confidence and buying pressure.

14.10.2024 - HIMS Stock was down 18.6%

• The stock's downturn today may be linked to Amazon.com Inc's introduction of fixed pricing for telehealth services, signaling potential competition concerns in the industry.
• Despite HIMS broadening its offerings and product range, it faces broader economic headwinds that could detract from its performance, influencing the negative stock trend.
• Ongoing bullish options trading on HIMS could reflect mixed investor sentiment, with some optimistic and others more cautious, resulting in heightened volatility and downward pressure on the stock.
• Positive revisions in earnings outlook for HIMS hint at long-term growth prospects. However, short-term market conditions and external factors are currently driving down the stock despite these positive forecasts.

04.11.2024 - HIMS Stock was up 5.4%

• The stock of HIMS experienced a strong bullish movement today.
• Despite the bearish moves made by financial giants, the surge in bullish options activity by deep-pocketed investors indicates a positive sentiment towards Hims & Hers Health.
• The conflicting actions of traders, with 20% being bullish and 70% showing bearish tendencies, might have created some volatility in the market.
• Overall, the bullish approach adopted by significant investors could have outweighed the bearish sentiment, leading to the strong upward movement in HIMS stock.

12.10.2024 - HIMS Stock was down 5.7%

• Despite optimistic positions from investors holding substantial Hims & Hers Health options, the market movement did not align positively with these stances, revealing a disparity between options trading patterns and stock behavior.
• Strong revisions in earnings estimates suggested a favorable future outlook, yet the stock followed a bearish trajectory, underscoring the volatile nature of the market.
• The significant interest in HIMS options by well-funded investors did not offset the market's bearish trend, underscoring how wider market sentiments can impact individual stock performance.

16.11.2024 - HIMS Stock was up 5.5%

• The stock showed significant upward momentum today.
• Q3 revenues were reported at $401.6 million, marking a 77% growth compared to the previous year, with a subscriber base exceeding 2 million.
• Investors are expressing optimism towards HIMS, evident in the unusual options activity.
• The company's optimistic forecast for 2024, aiming to surpass $1.5 billion in revenues, is likely boosting investor confidence and driving the stock's upward trend.

19.11.2024 - HIMS Stock was down 17.0%

• The stock of Hims & Hers Health saw significant downward movement today.
• This decline could be linked to the U.S. Food and Drug Administration's statement about tirzepatide injection shortages affecting the company's pharmaceutical line.
• Despite the recent decrease, the company has demonstrated promising growth potential with substantial revenues and subscriber numbers, suggesting a favorable outlook ahead if they can tackle supply chain issues effectively.